Octant Bio, Inc.

Venture capital investors continue to show their enthusiasm for drug development, despite the relative pessimism of their peers investing in publicly traded biopharmaceutical companies, by putting the

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Gets 5T4-Targeted NK Cell Therap

It took four weeks, but the second quarter of 2022 finally has its first two biopharmaceutical initial public offerings in the US, launched by HilleVax, Inc. and Belite Bio late on 28 April. The o